# US 2010/0166829 A1 · Active agent eluting matrices with particulates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166829 A1
- Document ID: US20100166829A1
- Status: Published application
- Kind: A1
- Application number: 12/647,780
- Filed: 2009-12-28
- Published: 2010-07-01
- Earliest claimed: 2006-06-28
- Assignees: SurModics, Inc.
- Inventors: Joram Slager; Aron B. Anderson
- Web page: https://patentgrep.com/patent/US20100166829A1

## CPC

- A61L 27/48: with macromolecular fillers
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 31/129: {containing macromolecular fillers}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/256: Antibodies, e.g. immunoglobulins, vaccines
- A61L 2300/622: Microcapsules
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The present invention is directed to polymeric matrices for the controlled release of a hydrophilic bioactive agent. Generally, the elution control matrix includes a polymeric matrix having a first polymer and a plurality of microparticles that include the hydrophilic bioactive agent. In one embodiment, the matrix includes a polymer comprising hydrophilic and hydrophobic portions. In another embodiment, the microparticles include a crosslinked hydrophilic polymer.

## Claims

### Claim 1

An elution control matrix for the controlled release of a hydrophilic bioactive agent, comprising a polymeric matrix comprising:
a first polymer that is hydrophobic, wherein a portion or all of the polymeric matrix is formed from the first polymer; and
a plurality of microparticles dispersed within the polymeric matrix; wherein the microparticles comprise a hydrophilic bioactive agent and crosslinked hydrophilic polymer.

### Claim 2 (depends on 1)

The elution control matrix of claim 1 wherein the microparticles comprise a polypeptide.

### Claim 3 (depends on 1)

The elution control matrix of claim 1, wherein the microparticles comprises a polypeptide that is an antibody or fragment thereof.

### Claim 4 (depends on 1)

The elution control matrix of claim 1, wherein the microparticles comprises a Fab fragment.

### Claim 5 (depends on 1)

The elution control matrix of claim 1, wherein the microparticles are formed predominantly of the hydrophilic bioactive agent.

### Claim 6 (depends on 1)

The elution control matrix of claim 1 wherein the first polymer is a biostable polymer.

### Claim 7 (depends on 6)

The elution control matrix of claim 6 wherein the first polymer is selected from the group consisting of poly(alkyl(meth)acrylates) and poly(aromatic(meth)acrylates).

### Claim 8 (depends on 7)

The elution control matrix of claim 7 wherein the first polymer comprises poly(n-butyl methacrylate).

### Claim 9 (depends on 1)

The elution control matrix of claim 1 further comprising a second polymer that is biodegradable.

### Claim 10 (depends on 1)

The elution control matrix of claim 1 further comprising a second polymer, wherein the weight ratio of the second polymer to the microparticles in the matrix is in the range of 0.5:1 to 1:1.

### Claim 11 (depends on 1)

The elution control matrix of claim 1 wherein the crosslinked hydrophilic polymer comprises a polysaccharide.

### Claim 12 (depends on 11)

The elution control matrix of claim 11 wherein the crosslinked hydrophilic polymer comprises a polysaccharide selected from the group consisting of maltodextrin and amylose.

### Claim 13 (depends on 1)

The elution control matrix of claim 1 wherein the microparticles are present in the matrix in an amount in the range of 30% to 70% by weight solids.

### Claim 14 (depends on 1)

The elution control matrix of claim 1 wherein the microparticles are present in the matrix in an amount in the range of 30% to 40% by weight solids.

### Claim 15 (depends on 1)

The elution control matrix of claim 1 which is in the form of a coating on an implantable medical device.

### Claim 16 (depends on 1)

The elution control matrix of claim 1 which is in the form of a coating on an implantable intraocular device.

### Claim 17 (depends on 1)

The elution control matrix of claim 1 wherein the hydrophilic polymer is crosslinked on the surface of the particle forming a coating or shell.

### Claim 18 (depends on 1)

The elution control matrix of claim 1 wherein the crosslinked hydrophilic polymer is crosslinked via polymerized groups pendent from the hydrophilic polymer.

### Claim 19 (depends on 1)

The elution control matrix of claim 1 wherein the crosslinked hydrophilic polymer is crosslinked via polymerized groups pendent from the hydrophilic polymer, wherein crosslinking is performed using a polymeric polymerization initiator comprising charged groups.

### Claim 20 (depends on 1)

The elution control matrix of claim 1 which is in the form of an implant.
